Over Mothers Day weekend 2011, Kimberly Schuetz took her 2-year-old son on a road trip from their hometown of Fall River, Wisconsin, to visit family in Illinois. Leading up to the journey, Austin had been his normal, energetic self.
He was eating like a horse and being very active, very playful. No sicknesses, fevers, or anything like that, Schuetz says.
On Saturday, Schuetzs father-in-law noticed something alarming while tickling his grandson. One of Austins lymph nodes on his neck had swollen to the size of a golf ball. As an oncology nurse, Schuetz immediately had a sick feeling in her stomach. Her mind went straight to thoughts of cancer.
While her gut reaction told her to take Austin to the emergency department, Schuetz decided to wait until Monday to visit his pediatrician back home. After all, her son was acting fine.
A week later, after visits to two pediatricians, the emergency department at their local hospital and pediatric hematologists at a childrens hospital, a bone marrow biopsy confirmed that Austin had acute lymphoblastic leukemia (ALL). A cancer of the blood and bone marrow, ALL is the most common type of cancer that occurs in children.
I literally felt like I was living somebody elses life, like I was watching a movie. I remember sitting there and listening to the doctor, but I also felt like I was floating above myself, Schuetz says. I was numb and couldnt cry. Your brain just goes into this state of shock.
Omar Durani, a family physician in Dallas, Texas, went through similar feelings when his 9-month-old daughter Kenza received an acute myeloid leukemia (AML) diagnosis. In 2016, her swollen lymph nodes signaled to Durani and his wife that something wasnt right.
As a physician and dad, its kind of difficult to figure out what hat to wear when, and how much to worry about things like that, he says. When the swelling worsened, we started advocating for blood work, but all the doctors we visited only kept giving her antibiotics.
Finally, an emergency department physician who Durani knew personally listened to their concerns and performed blood testing. The results came back with white cell counts through the roof, confirming the familys worst fears: Kenza had cancer.
Both ALL and AML are treated initially with chemotherapy, and for the vast majority of children, it works. More than 95% of children with ALL and about 85% to 90% of those with AML enter remission after the first phase of chemotherapy. However, remission does not necessarily mean a cure.
Austin relapsed in October 2012 after two phases of chemotherapy, and despite receiving a bone marrow transplant, his ALL came back a third time in May 2013. About 10% to 20% of children with ALL have a disease that relapses or is resistant to treatment. At that point, with no treatment options left, Austins parents were told he had three to six months to live.
We live 45 minutes away from the hospital, and our doctor ended up driving to our house, not to offer any solutions, because we didnt have a plan, but just to sit and cry with us, because she was so heartbroken and, in such disbelief, Schuetz says.
Some cancer in children does not respond to chemotherapy. After three rounds of chemotherapy, doctors told Durani that his daughters only hope would be a bone marrow transplant. But as a child of Asian descent and mixed ethnic background, Kenza had a less than 2% chance of finding a bone marrow donor match.
While research in adult blood cancers has led to an explosion of new targeted therapies and immunotherapies, such progress has been slower for younger patients. This can leave children such as Austin and Kenza without a path forward. Even for patients who do achieve long-term survival, the lingering toxicity of chemotherapy can lower their quality of life as adults.
Only four cancer treatments have been approved for first use in children in the last 40 years, compared with hundreds approved for treating adults during this same time frame, said Dr. Gwen Nichols, chief medical officer of the Leukemia & Lymphoma Society (LLS).
Out of all the federal funding that goes into cancer research, only 4% goes toward pediatric cancer research, said Dr. Deepa Bhojwani, director of the Leukemia and Lymphoma Program
at Childrens Hospital Los Angeles in California. That being said, I would say within the last five to 10 years, there has been a lot more progress in terms of targeted treatment and immunotherapy than there was in the past.
But the tide may be turning for this young, vulnerable population with new research initiatives dedicated to applying precision medicine to pediatric blood cancers. Much of todays research in pediatric blood cancers aims to find tailored alternatives to chemotherapy that could prove just as or more effective with fewer harmful side effects.
Cancer is still the leading cause of death from disease among children and adolescents in the United States. From 2012 to 2016, leukemia and lymphoma accounted for 38.7% of all cancer types for patients under age 20. Approximately 40% of children with AML and 20% of those with ALL experience a relapse of their disease. Non-Hodgkin lymphoma, the most common type of lymphoma in children under age 14, that is resistant to first-line therapy has a very poor prognosis.
Before joining LLS, Nichols worked for a pharmaceutical company. She says that getting pediatric drugs tested and approved may be difficult because they typically do not bring in as much revenue as adult therapies.
As a result, upon arriving at LLS she was determined to figure out a faster, more efficient way to bring new agents and therapies to children with blood cancers.
In 2016, LLS launched the Beat AML Master Trial for adults with AML. It represented a paradigm shift in the format of clinical trials by testing several different targeted therapies in individual study arms instead of only one drug or combination of drugs at a time. Patients had a genomic screening to determine whether they had one of the genetic mutations that would make them eligible for one of the study arms to test a particular targeted therapy.
Its about 50% less expensive to do a master trial than it is to do one drug at a time. So, we needed to do something similar in pediatrics to make it more cost-efficient. But even more than that, if you want to get targeted therapies to kids, you have to have the right kids to test the drug, Nichols said. If youre doing one drug at a time, you have to screen thousands of kids to find the five that fit your drug, which costs time and money.
In 2019, LLS announced a collaboration with the National Cancer Institute and the Childrens Oncology Group called LLS PedAL (Pediatric Acute Leukemia), a global precision medicine master clinical trial in the same vein as the Beat AML trial. Children with relapsed acute leukemia will undergo genomic screening to match the specific abnormalities driving their cancer with one of several targeted therapies.
As part of The LLS Childrens Initiative: Cures and Care for Children, a $100 million, multiyear effort to take on pediatric blood cancers, LLS PedAL will test multiple agents simultaneously at up to 200 sites worldwide. Trials will follow the same format so that data from multiple institutions can be shared and consolidated.
Nichols and her colleagues hoped to begin the trial this year, but with the coronavirus disease 2019 pandemic, LLS PedALs start date has been pushed back to early 2021.
Another inspiring research project is the Pediatric Cancer Genome Project (PCGP), a joint initiative from St. Jude Childrens Research Hospital and Washington University School of Medicine. Since 2010, the two insti- tutions have pioneered efforts to define the genomic landscape of pediatric cancer by sequencing the genomes of normal and cancer cells from 800 patients.
That work really filled in much of the landscape of mutations that drive ALL, AML and many of the other kinds of pediatric cancer, says Dr. James R. Downing, president and CEO of St. Jude, who was instrumental in launching the PCGP. In particular, important fundamental discoveries came out for ALL in terms of new understandings related to the identification of new genetic subtypes, amplifications, fusions and chromosomal translocations of the disease.
For instance, the PCGP pinpointed genes linked to an ALL subtype with a poor prognosis known as Philadelphia chromosome-like ALL (Ph-like ALL). In 2009, St. Jude scientists were among the first to describe Ph-like ALL in children. Five years later, next-generation sequencing revealed the genetic alterations that give rise to Ph-like ALL, which could be targeted with drugs widely used to treat other types of leukemia more common in adults.
A 2017 study from the PCGP identified potential targets for immunotherapies in pediatric cancers, finding that 88% of leukemias have at least one that could be exploited. A 2018 pan-cancer analysis that examined commonalities and differences among various cancer types, including ALL and AML, suggest that half of the cancers studied may have a targeted treatment available or under development.
The second phase of the genome project is moving all that technology into frontline diagnostics, Downing says. So now were getting the whole genome, whole exome and RNA sequencing of every patient, and we gain insight that can be funneled into a protocol that allows them to be treated.
St. Judes frontline ALL protocol includes an unparalleled level of genomic sequencing on the patient, on both cancer and normal cells, which allows physicians to make personalized therapeutic decisions. Downing hopes that collecting such a wealth of data will help usher in new therapies and lead to a further improvement in outcomes.
So the momentum is there, the studies are ongoing, and hopefully five years from now, we will have a huge variety of therapies to offer our kids instead of just one, Bhojwani says.
Bhojwani participates in the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) consortium, which has its headquarters at Childrens Hospital Los Angeles. TACL brings together childrens hospitals and universities to accelerate the progress of new therapies for pediatric leukemia and lymphoma. The consortium includes 31 institutions in the United States and Australia that collaborate on clinical trials of new drugs and novel therapy combinations in the hopes of expanding the number of treatments available.
Both Kenza and Austin were saved by an experimental treatment called chimeric antigen receptor (CAR)-T cell therapy administered in a clinical trial. It involves engineering the bodys T cells, a type of white blood cell, to produce receptors on their surface called chimeric antigen receptors (CARs). The engineered cells are infused back into the patient, where they can recognize and kill cancer cells.
The Duranis couldnt find a bone marrow donor match for Kenza, despite having more than 60 donor drives inspired by her diagnosis that registered more than 5,000 new potential bone marrow donors around the country. At that point, they decided to move forward with CAR-T cell therapy coupled with a haploidentical, or partially matched, stem cell transplant in August 2016.
It was a no-brainer for us since there were no other therapies available besides a standard bone marrow transplant, Durani says. Now Kenzas been in remission for four years, and shes doing fantastic. Shes a thriving, spunky 5-year-old.
After his third relapse, Austins parents enrolled him in a clinical trial to receive CAR-T cell therapy as a last- ditch effort to save their son. He received the treatment at the beginning of October, and on Halloween which also happens to be his mothers birthday they received the good news that his biopsy showed no traces of cancer.
I immediately started screaming and crying. I was just elated. It was the best birthday present that I could ever, ever have. Nothing will ever top that, Schuetz says.
Today, Austin is a typical 12-year-old boy who enjoys video games, swimming with his friends and complaining about household chores. He and Kenza are living proof that innovations such as CAR-T cell therapy give children who have run out of options another chance at life.
- Doctor: COVID-19 cases will continue to slowly go down, but were not out of the woods - Yahoo Money - January 23rd, 2021
- Global Precision Medicine Market With COVID 19 Impact Analysis| Leading Players In-depth Analysis Research Report Foresight to 2027 - KSU | The... - January 23rd, 2021
- Leading Urologist Doubles Down on CaverStem Regenerative Stem Cell Procedure for Treatment of Erectile Dysfunction in Men - PRNewswire - January 22nd, 2021
- Sisters who organised an Ilkley fundraising ball are to be honoured - Wharfedale Observer - January 22nd, 2021
- Medical Doctor: Roes Overlooking of the Consensus of Societal Morality and Science Reverberates to This Day - National Catholic Register - January 22nd, 2021
- DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL)... - January 22nd, 2021
- Seattle researchers find clues for treatments that could eliminate HIV in infected patients - GeekWire - January 14th, 2021
- Flow Cytometry Market is Projected to Reach a Value of US$8100 Mn by the End of 2025 - KSU | The Sentinel Newspaper - January 14th, 2021
- Doctors diagnosed a Suffolk teen with a rare condition. Now, his mom is part of the solution - 13newsnow.com WVEC - January 12th, 2021
- Cassville club assists 2 families as they recover from illness - telegraphherald.com - January 12th, 2021
- The 26 billion-dollar startups to watch that are revolutionizing healthcare in 2021 - Business Insider - January 12th, 2021
- Global Precision Medicine Market 2020 Overview By Size, Share, Trends, Growth Factors and Leading Players With Detailed Analysis of Industry Structure... - January 12th, 2021
- More than 250 articles and a book later, the Valley Doctor bids adieu - San Lorenzo Valley Press-Banner - January 12th, 2021
- Groundbreaking Treatment for Severe COVID-19 Using Stem Cells It's Like Smart Bomb Technology in the Lung - SciTechDaily - January 5th, 2021
- New combo therapy offered against refractory T-cell lymphoma - Korea Biomedical Review - January 5th, 2021
- Hair Growth Treatment Secrets Bollywood Will Never Tell You About - Times of India - January 5th, 2021
- Are metabolic hormones the next frontier in cancer treatment? - MedCity News - January 5th, 2021
- Limerick toddler to wait six months for trial cancer treatment after family raises over 400,000 - Extra.ie - January 5th, 2021
- West Lothian mum fighting for her life after back pain turned out to be terminal blood cancer - Edinburgh Live - January 5th, 2021
- MorphoSys and Incyte Announce the Acceptance of the Swissmedic Marketing Authorization Application for Tafasitamab - Yahoo Finance UK - January 5th, 2021
- A Wish Come True urges plungers to dump a bucket of ice water on themselves for this year's fundraiser - Fall River Herald News - December 26th, 2020
- Ashley Cain says over 80,000 people registered for stem cell donation in 48 hours after appeal to save baby - The Sun - December 22nd, 2020
- The 11 most mind-blowing, awe-inspiring health discoveries and innovations of 2020 - Business Insider - Business Insider - December 22nd, 2020
- 3-year-old patient successfully treated for rare fatal disease- familial Hemophagocytic lymphohistiocytosis (HLH) at Fortis Hospital Shalimar Bagh -... - December 22nd, 2020
- Startups are racing to reproduce breast milk in the lab - MIT Technology Review - December 22nd, 2020
- Hand weakness: Causes, symptoms, treatment, and seeking help - Medical News Today - December 22nd, 2020
- Gujarat Issues Health Advisory On Fungal Infection With "50% Mortality Rate" - NDTV - December 22nd, 2020
- A side-by-side comparison of the Pfizer/BioNTech and Moderna vaccines - STAT - December 22nd, 2020
- City of Hope Doctors Present Innovative Therapies to Better Treat Blood Cancers at American Society of Hematology Virtual Conference - Business Wire - December 9th, 2020
- Medical technologies that will disrupt (and improve) healthcare in the 2020s - Universe.byu.edu - December 9th, 2020
- Community Cord Blood Banking saves life of child with aplastic anaemia - The Hindu - November 20th, 2020
- Arya Lloyd: Father launches global search for blood stem cell donor to save his 12-year-old daughter - Sky News - November 20th, 2020
- Blood Cancer: Science Reveal Five Easily Missed Signs of Leukemia - Science Times - November 20th, 2020
- Karnataka:Community cord blood banking emerges as lifesaver - United News of India - November 18th, 2020
- How CAR-T Cell Therapy is Being Used in the Field of Blood Cancer Treatment - Curetoday.com - November 16th, 2020
- Election results for California Propositions 14, 18, 23, and 24 - FOX 11 Los Angeles - November 16th, 2020
- Cell Separation Beads Market to Witness Robust Expansion Throughout the Forecast Period 2018-2028 - The Daily Philadelphian - November 16th, 2020
- Fight for the rights of unborn - The Daily Telegram - November 11th, 2020
- Genetic Mechanism Identified in Neonatal Diabetes Could Offer Insights into Other Forms of the Disease - Genetic Engineering & Biotechnology News - November 11th, 2020
- Doctors Debate: Is Intensive or Low-Intensity Chemotherapy Plus BCR-ABL TKI Therapy Best for Treatment of Ph+ ALL? - Targeted Oncology - November 11th, 2020
- Record number of stem cell donors apply after Ex On The Beach star plea - expressandstar.com - November 11th, 2020
- Bisbee: A commitment to health care initiatives The Journal Record - Journal Record - November 11th, 2020
- California election results: Where state propositions stand as of Thursday at 5 p.m. - Desert Sun - November 11th, 2020
- Critically ill Indonesian woman thanks Taiwan for saving life - Taiwan News - November 7th, 2020
- City of Hope Doctors Present New Research on Bone Marrow Transplants, Immunotherapy and Other Blood Cancer Treatments - Business Wire - November 7th, 2020
- Daily Edition for Wednesday, November 4, 2020 - California Healthline - November 7th, 2020
- 'We're truly blood brothers' - Stanford coach David Shaw and his recent fight to save his brother, Eric - ESPN - November 7th, 2020
- 'We're really blood brothers' - Stanford coach David Shaw and his current battle to save lots of his brother, Eric - The Shepherd of the Hills Gazette - November 7th, 2020
- Mark Drought: Are we on the brink of another civil war? - The Advocate - November 7th, 2020
- What to eat when you have the flu, recommended by doctors - Business Insider India - October 30th, 2020
- Fine-Tuning Treatments for COVID-19 - American Council on Science and Health - October 30th, 2020
- Aborted girl fetus kidneys made Trumps CoV meds. As SARS2 is unfettered in America, this needs thought - Feminine-Perspective Magazine (FPMag) - October 30th, 2020
- What to Know in Washington: Provisional Ballots May Play Role - Bloomberg Government - October 30th, 2020
- Unless the country invests in cancer care, the statistics for breast cancer will be bleak: Dr Anthony Pais, .. - ETHealthworld.com - October 23rd, 2020
- Autologous Fat Grafting Market Scope Analysis 2019 to 2029 - The Think Curiouser - October 23rd, 2020
- How Clinique La Prairie Is Keeping Humanity Fashionably Healthy In The Age Of Covid - Forbes - October 23rd, 2020
- The Anthony Nolan and NHS Stem Cell Registry - The Hippocratic Post - October 21st, 2020
- Jeff Bridges is one of the 85,000-plus lymphoma cases expected in the U.S. this year - MarketWatch - October 21st, 2020
- YOUR HEALTH: Saving an unborn baby breaking apart in the womb - WQAD.com - October 21st, 2020
- Orgenesis completes acquisition of Koligo Therapeutics and announces additional acquisition of Icellator(R) Technology from Tissue Genesis in related... - October 21st, 2020
- SA becomes 2nd country to allow 16 and 17-year-olds to donate bone marrow - News24 - October 21st, 2020
- Stem Cell Therapy Market to Witness Steady Expansion During 2025 KYT24 - KYT24 - October 21st, 2020
- Mohammed Hussain Alqahtani shares his insights about the evolution of plastic surgery - LA Progressive - October 21st, 2020
- Manya Saaraswat Makes Top 5 Finish in 2020 Miss World America Competition, Three Other Indian Americans in Top 10 - India West - October 21st, 2020
- Banking wisdom: Teen saving stem cells in hopes of future treatment - LubbockOnline.com - October 15th, 2020
- Mohammed Hussain Alqahtani Discusses the Future of Plastic Surgery - The Jerusalem Post - October 15th, 2020
- The story of how a biotech co. came to the aid of an ill 9-year-old boy - Stockhouse - October 15th, 2020
- Where Amy Coney Barrett Stands on IVF - Glamour - October 15th, 2020
- Regeneron, Trump, and the alleged hypocrisy of the pro-life movement - Christian Post - October 15th, 2020
- Life Sciences - a year to remember - Lexology - October 15th, 2020
- Proposition 14: With Handful of Cures, Calif. Stem Cell Agency Has Mixed Record. Will Voters Pony Up Another $5.5 Billion? - KQED - October 8th, 2020
- Woman who lost her partner to cancer last year set to run 10K in his memory - Warrington Guardian - October 8th, 2020
- Different Types of Childhood Cancer | INTEGRIS - Integris - October 3rd, 2020
- A perfect match: Bone marrow transplant saves twin brother's life. Now their family pays it forward - 11Alive.com WXIA - October 3rd, 2020
- Baby whose nosebleeds turned out to be deadly condition saved by stranger - Mirror Online - October 3rd, 2020
- Over 40 lakh people in Telangana have developed COVID-19 antibodies: Health Minister Eatala - The New Indian Express - October 3rd, 2020
- World Rose Day 2020: History and significance of the welfare of cancer patients - Hindustan Times - September 23rd, 2020
- Guide to Voting on Propositions and the City of San Bernardino's Measure S - Black Voice News - September 23rd, 2020
- Blood Cancer Awareness Month 2020 - Everyday Health - September 23rd, 2020
- CARLTON FLETCHER: McConnell is the poster boy for sleazy, partisan politics - The Albany Herald - September 23rd, 2020